ASH 2022: Trials Show Promising Results in Follicular Lymphoma
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Diagnosis & Disease Information
Glofitamab Can Provide Lasting Remissions in Heavily Pretreated Large B-Cell Lymphoma
Progression is “uncommon” in patients with relapsed/refractory large B-cell lymphoma who are in complete remission at the end of glofitamab treatment.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Zandelisib Plus Zanubrutinib Elicits High ORRs in Relapsed/Refractory FL or MCL
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
BTK Inhibitor With CAR T-Cell Therapy Deemed Effective in Relapsed/Refractory MCL
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Remote Assessment of Cognitive Function Feasible With Hematologic Malignancies
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Consolidative Stem Cell Transplant May Improve Outcomes in PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Atezolizumab Plus R-CHOP Deemed Unworthy of Additional Study in Diffuse Large B-Cell Lymphoma
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...